Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Identifiable Intangible Assets Carrying Value (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)
Diagnostic Test, Thyroid [Member] \| Asuragen [Member]
Finite-lived intangible asset, useful life	9 years
Finite-Lived Intangible Assets, Net	$ 8,519
Diagnostic Test, Pancreas [Member] \| Asuragen [Member]
Finite-lived intangible asset, useful life	7 years
Finite-Lived Intangible Assets, Net	$ 2,882
Diagnostic Test, Pancreas [Member] \| RedPath [Member]
Finite-lived intangible asset, useful life	7 years
Finite-Lived Intangible Assets, Net	$ 16,141
Diagnostic Test, Biobank [Member] \| Asuragen [Member]
Finite-lived intangible asset, useful life	4 years
Finite-Lived Intangible Assets, Net	$ 1,575
Diagnostic Test, Barrett's RedPath [Member] \| RedPath [Member]
Finite-lived intangible asset, useful life	9 years
Finite-Lived Intangible Assets, Net	$ 18,351
CLIA Diagnostic Lab [Member]
Finite-lived intangible asset, useful life	2 years 109 days
Finite-Lived Intangible Assets, Net	$ 609
RedPath [Member]
Finite-Lived Intangible Assets, Net	47,468
Finite-Lived Intangible Assets, Net	42,522
Finite-Lived Intangible Assets, Accumulated Amortization	$ (5,555)